January 12, 2026
Nature Communications reports Promising Effect of Idorsia’s Lucerastat on Kidney Function in Fabry Disease
January 6, 2026
Idorsia Initiates a Proof-of-Concept Trial with its Oral First-in-Class Selective CCR6 Antagonist
No current content.
